L-carnitine
Other / unclassified targets PPARG
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | CARNITOR | — | 1992-12-16 – 1999-12-15 | fda.gov ↗ |
| Approved | US (FDA) | CARNITOR | — | 1985-12-27 | fda.gov ↗ |
Trials 75 · started per year
Also used as a comparator or background therapy in 36 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06342856 Comparator | Jun 2023 → Jun 2024 | oligospermia | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT05487781 Background | May → Jun 2022 | — | Molecule X LLC | Unknown | No outcome recorded |
| Phase 0 | NCT03953248 Comparator | Jan 2016 → Jan 2018 | poisoning | Heba Allah Ali Abd El-Halim Mabrouk | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07216001 Background | May 2026 → Dec 2027 expected | autism, childhood apraxia of speech | Claudia R. Morris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07108777 Comparator | Aug 2025 → Aug 2026 overdue | cisplatin toxicity | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT03164421 Comparator | Jan 2017 → Jun 2018 | polycystic ovary syndrome | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT00481013 Comparator | Jul 2007 → Dec 2009 | spinal muscular atrophy | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00809042 Comparator | Jun → Nov 2007 | beta-thalassemia intermedia | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00000912 Background | ? → May 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00002379 Background | — | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00002184 Background | — | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00002219 Background | — | HIV infectious disease | Gilead Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00000885 Background | ? → Jun 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001087 Background | ? → Jul 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03021876 Comparator | Apr 2016 → Apr 2018 | — | Kochi University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01580553 Comparator | Jan 2011 → Mar 2012 | heart failure | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05792527 Comparator | Mar 2023 → Mar 2025 | rheumatoid arthritis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05584956 Comparator | Jul 2022 → Jul 2023 | beta thalassemia | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT03426722 Comparator | Mar 2018 → Dec 2019 | gastrointestinal stromal tumor | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02792088 Background | Jul 2015 → Feb 2020 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02007889 Comparator | Nov 2013 → Aug 2014 | acute pyelonephritis | Shahid Beheshti University | Unknown | No outcome recorded |
| Phase 3 | NCT01671384 Comparator | Aug 2013 → Dec 2016 | spinal muscular atrophy | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01107730 Comparator | Apr 2010 → Apr 2015 | atrial fibrillation | Attikon Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00001082 Background | Dec 1996 → Jan 1999 | HIV infectious disease, cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07642076 Comparator | Jun → Dec 2026 expected | liver disorder | Beni-Suef University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04202536 Background | May 2019 → Jun 2021 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT04434404 Comparator | Sep 2018 → Aug 2019 | breast cancer | Horus University | Completed | No outcome recorded |
| Phase 4 | NCT05081349 Comparator | Jan 2017 → Jun 2020 | sickle cell disease | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT01769157 Comparator | Aug 2012 → Jun 2013 | hypothyroidism | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01665547 Comparator | Jul 2012 → Aug 2013 | — | Woman's Health University Hospital, Egypt | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07016867 Comparator | Sep 2024 → Aug 2025 overdue | spermatogenic failure | South Valley University | Recruiting | No outcome recorded |
| — | NCT06122012 Background | May 2023 → Apr 2024 | diabetic polyneuropathy | Haisco Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| — | NCT05083637 Comparator | Oct 2021 → Mar 2023 | protein-energy malnutrition | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| — | NCT01523106 Comparator | Aug 2013 → Feb 2014 | Crohn disease | University of California, San Francisco | Withdrawn | No outcome recorded |
| — | NCT00002398 Background | — | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| — | NCT00000892 Background | ? → Aug 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 116 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Carnitine | “L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day...” NCT04434404 ↗91“food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “The purpose of the study to assess the efficacy of adding L-carnitine to clomiphene citrate for increasing the ovulation and the pregnancy rate in women with PCOS.” NCT03476356 ↗ “This group will receive the standard chemotherapy protocol (cisplatin -based chemotherapy) plus L-carnitine 350 mg (L-carnitine®) three times daily by oral.” NCT07108777 ↗ “Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients.” NCT00858182 ↗ “The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up” NCT05083637 ↗ “The study product is blend of ingredients composed of L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate (DNF-10®).” NCT06689501 ↗ “First, the investigators will include L-carnitine to enhance the transport of fatty acids across the mitochondrial membrane” NCT04330326 ↗ “L-carnitine is an important factor in fatty acid metabolism, and carnitine deficiency is common in dialysis patients.” PMID 33139659 ↗ Nov 2020 “Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.” NCT04044131 ↗ “This study evaluates the impact of the treatment with L-Carnitine on the function of adults over 65 years” NCT03180424 ↗ “L-Carnitine, a natural substance present in the body, is essential for energy metabolism in mammals.” NCT07642076 ↗ “Oral Levocarnitine (L-Carnitine), 2970mg daily dose (990mg taken 3 times a day) for 3 months.” NCT07201714 ↗ “Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®” NCT04202536 ↗ “perioperative treatment with l-carnitine (carnitine group) or usual intake (control group)” PMID 31599019 ↗ Oct 2019 “l-carnitine stabilizes red blood cell membranes and thus improves the anemic state” NCT05584956 ↗ “L-carnitine (LC) plays an important physiologic role in lipid metabolism.” PMID 27317162 ↗ Jun 2016 “Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day” NCT07437391 ↗ “L-Carnitine 1000 mg capsule administered orally once daily for 3 months.” NCT07669402 ↗ “IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution” NCT04086212 ↗ “will receive L-carnitine 1 tablet per day orally for 3 months” NCT06342856 ↗ “L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.” NCT02792088 ↗ “L-Carnitine is a nutritional supplement” NCT06753565 ↗ “L-Carnitine ( high dose)” NCT05322447 ↗ “Drug: L-Carnitine” NCT00322322 ↗ |
| Known as | Carnitene | “All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.” NCT03230812 ↗ |
| Known as | carnitine | “Carnitine is the essential cofactor for various enzyme activities of human metabolism, especially for the mitochondrial carnitine shuttle that transfers long-chain fatty acids...” NCT00841295 ↗ |
| Known as | Carnitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02722902 ↗ |
| Known as | L-Carnitina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05487781 ↗ |
| Known as | L-carnitine hydrochloride | “HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；” NCT06122012 ↗ |
| Known as | L-carnitine tartrate | “Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).” NCT04573153 ↗ |
| Known as | L-carnitine: Carnitor | “L-carnitine: Carnitor” NCT00202228 ↗ |
| Known as | Levocarnitine | “Several experimental studies have shown that levocarnitine reduces myocardial injury after ischemia and reperfusion by counteracting the toxic effect of high levels of free...” PMID 15591005 ↗ Nov 200427“Levocarnitine (L-carnitine) is a micronutrient found in meat and dairy products that plays a major role in energy metabolism.” NCT00079599 ↗ “All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.” NCT03230812 ↗ “Drug: Valproic Acid and Levocarnitine; capsules” NCT00481013 ↗ |
| Modality | Other / unclassified | “L-carnitine is an amino acid derivative that is thought to be helpful for treating renal anemia in hemodialysis patients.” PMID 33713287 ↗ Mar 2021 |
| Route | Oral | “500 mg tablet taken orally daily” NCT00001082 ↗ |
| Target | PPARG | “LC also have anti-inflammatory effect by acting on PPAR gamma” NCT06753565 ↗ |